$I Billion for Injured New Yorkers
  • $30.1 Million NYC - Medical Malpractice Case
  • $15 Million Manhattan - Medical Malpractice Case
  • $3 Million Queens - Wrongful Death Case
  • $5.5 Million Bronx - Birth Injury Accident
  • $30.1 Million NYC - Medical Malpractice Case
  • $15 Million Manhattan - Medical Malpractice Case
  • $3 Million Queens - Wrongful Death Case
  • $5.5 Million Bronx - Birth Injury Accident
  • $7.75 Million NYC - Medical Malpractice Case
Rosenberg, Minc, Falkoff & Wolff, LLP - New York Medical Malpractice Lawyers
Experienced & Trusted Medical Malpractice Lawyers
Call today for a Free Consultation
1-866-516-5887
Header
Rated 5 / 5 based on 5 reviews.

COMMON PROCEDURE USED TO TREAT FIBROIDS AND CONDUCT HYSTERECTOMY & MYOMECTOMY IN WOMEN FOUND TO SPREAD CANCER

On April 17, 2014, the United States Food and Drug Administration (the "FDA") issued a News Release in which it discouraged the use of laparoscopic power power morcellation for the removal of the uterus (i.e., a hysterectomy) or the removal of uterine fibroids (i.e., a myomectomy) in women because, according to the FDA's research, the treatment can cause the spreading of certain cancers. If a woman that has a type of cancer known as a "uterine sarcoma" undergoes laparoscopic power power morcellation, the FDA has determined that the risk of spreading the cancer throughout the patient's abdomen and pelvis is significantly elevated, and the chances of long-term survival are severely diminished. According to currently-available data, the FDA has determined that approximately 1 in 35 women undergoing a hysterectomy or myomectomy for fibroids have a uterine sarcoma.

On April 17, 2014, the United States Food and Drug Administration (the "FDA") issued a News Release in which it discouraged the use of laparoscopic power power morcellation for the removal of the uterus (i.e., a hysterectomy) or the removal of uterine fibroids (i.e., a myomectomy) in women because, according to the FDA's research, the treatment can cause the spreading of certain cancers. If a woman that has a type of cancer known as a "uterine sarcoma" undergoes laparoscopic power power morcellation, the FDA has determined that the risk of spreading the cancer throughout the patient's abdomen and pelvis is significantly elevated, and the chances of long-term survival are severely diminished. According to currently-available data, the FDA has determined that approximately 1 in 35 women undergoing a hysterectomy or myomectomy for fibroids have a uterine sarcoma.

If you or someone you know has been treated with laparoscopic power power morcellation in the context of a hysterectomy, myomectomy or for any other reason, please call our office for a free consultation regarding whether you may be entitled to compensation.

The full text of the FDA's News Release can be found here.

LEARN ABOUT MEDICAL MALPRACTICE CASES IN NYC

LISTEN TO OUR CLIENTS

Office Locations - Call today to schedule a consultation 1-866-516-5887

16 Court Street
|
Brooklyn, NY 11241|

Brooklyn Law Office

3101 Broadway
|
Astoria, NY 11106|

Astoria Law Office

8900 Sutphin Blvd
Suite 501
|
Queens, NY 11435|

Queens Law Office

9201 4th Ave
|
Brooklyn, NY 11209|

Brooklyn Law Office

Firm News

Robert H. Wolff Named President
Firm Attorney, Robert H. Wolff is now the president of the New York City Bronx County Bar Association
About This Attorney